OmniAb to Participate in Two Investor Conferences in November
November 02 2023 - 8:00AM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) today announced that
management will be participating in two upcoming investor
conferences in November.
- Stifel 2023 Healthcare Conference, November 14-15, 2023 at
the Lotte New York Palace Hotel in New York City. Management
will participate in a fireside chat on Wednesday, November 15th at
8:00 a.m. Eastern time and will be available for one-on-one
meetings with investors.
- 14th Annual Craig-Hallum Alpha Select Conference,
November 16, 2023 at the Sheraton New York Times Square Hotel in
New York City. Management will be hosting one-on-one meetings
during the event.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications though a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep™, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102069888/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Sep 2024 to Oct 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Oct 2023 to Oct 2024